Suppr超能文献

年龄相关性黄斑变性的分期、发病机制、临床管理及治疗进展。

Stages, pathogenesis, clinical management and advancements in therapies of age-related macular degeneration.

机构信息

UR Advanced Therapeutics Private Limited, ASPIRE-BioNest, School of Life Sciences, University of Hyderabad, Gachibowli, Hyderabad, 500046, India.

Centre de Recherche Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada.

出版信息

Int Ophthalmol. 2023 Oct;43(10):3891-3909. doi: 10.1007/s10792-023-02767-2. Epub 2023 Jun 22.

Abstract

Age-related macular degeneration (AMD) is a retinal degenerative disorder prevalent in the elderly population, which leads to the loss of central vision. The disease progression can be managed, if not prevented, either by blocking neovascularization ("wet" form of AMD) or by preserving retinal pigment epithelium and photoreceptor cells ("dry" form of AMD). Although current therapeutic modalities are moderately successful in delaying the progression and management of the disease, advances over the past years in regenerative medicine using iPSC, embryonic stem cells, advanced materials (including nanomaterials) and organ bio-printing show great prospects in restoring vision and efficient management of either forms of AMD. This review focuses on the molecular mechanism of the disease, model systems (both cellular and animal) used in studying AMD, the list of various regenerative therapies and the current treatments available. The article also highlights on the recent clinical trials using regenerative therapies and management of the disease.

摘要

年龄相关性黄斑变性(AMD)是一种常见于老年人群的视网膜退行性疾病,可导致中心视力丧失。如果不能预防,疾病的进展可以通过阻止新生血管生成(AMD 的“湿性”形式)或通过保护视网膜色素上皮和光感受器细胞(AMD 的“干性”形式)来进行管理。尽管目前的治疗方法在延缓疾病进展和管理方面取得了一定的成功,但近年来在使用 iPSC、胚胎干细胞、先进材料(包括纳米材料)和器官生物打印进行再生医学方面的进展,为恢复视力和有效管理 AMD 的两种形式提供了广阔的前景。这篇综述重点介绍了疾病的分子机制、用于研究 AMD 的细胞和动物模型系统、各种再生疗法的列表以及现有的治疗方法。文章还强调了最近使用再生疗法治疗疾病和管理疾病的临床试验。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验